Role of Rivaroxaban in Patients with Cerebral Venous Thrombosis

  • Syed Arslan Haider Department of Neurology, Punjab Institute of Neurosciences, Lahore Pakistan.
  • Huma Batool Department of Pulmonology, Lahore General Hospital (LGH), Lahore Pakistan.
  • Shahid Mukhtar Department of Neurology, Sheikh Zayed Hospital, Lahore Pakistan.
  • Athar Iqbal Department of Neurology, Sheikh Zayed Hospital, Lahore Pakistan.
  • Shoaib Luqman Department of Neurology, Bahawalpur Victoria Hospital, Bahawalpur, Pakistan.
  • Adnan Tariq Department of Neurology, Mayo Hospital, Lahore Pakistan.
Keywords: Cerebral Venous Thrombosis, Prothrombin Time, Activated Partial Thromboplastin Time, Space Occupying Lesion


Objective:  Cerebral venous thrombosis is a common neurological disease. It has been treated so far with Warfarin that needs continuous monitoring of PT (prothrombin time) and INR (International Normalization Ratio) with potential complications due to this problem. Newer oral anticoagulants have been recommended for other thromboembolic events like pulmonary embolism and can be a good alternative treatment of CVT. We determined the effectiveness of new oral anticoagulant Rivaroxaban in patients with cerebral venous thrombosis.

Material and Methods:  The study was conducted in the indoor department of Neurology, Punjab Institute of neurosciences for 1year. Magnetic cerebral venography (MRV) Brain was done at the start of Rivaroxaban, at 3 months and at 6 months where needed. The bias effect was removed by getting MRV done and reported from the same department.

Results:  A total of 18 patients were enrolled in the study. One patient was lost to followup. Mean age of our patient data was 28.66 ± 6.66. 16 (88%) patients were females and 2 (11%) were males. 9 patients (50%) had clinical and radiological recovery based on MRV brain at 3 months.7 patients (38%) had recovery based on clinical and radiological parameters at 6 months. Only 1 patient had partial recanalization but that also improved clinically.

Conclusion:  Rivaroxabancan is a very effective alternative for warfarin in cerebral venous sinus thrombosis which will avoid concerns commonly encountered with warfarin.


1. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007; 6: 162–170.
2. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke, 2004; 35: 664–670.
3. Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombo15sis. Neurology, 1999; 53: 1537–1542.
4. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998; 338: 1793–1797.
5. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol. 2005; 106: 509–516.
6. Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol. 2004; 24: 453–460.
7. Damak M, Crassard I, Wolff V, Bousser MG. Isolated lateral sinus thrombosis: a series of 62 patients. Stroke, 2009; 40: 476–481.
8. Cucchiara B, Messe S, Taylor R, Clarke J, Pollak E. Utility of D-dimer in the diagnosis of cerebral venous sinus thrombosis. J Thromb Haemost. 2005; 3: 387–389.
9. Leach JL, Fortuna RB, Jones BV, Gaskill-Shipley MF. Imaging of cerebral venous thrombosis: current techniques, spectrum of findings, and diagnostic pitfalls. Radiographics, 2006; 26 (Suppl. 1): S19–S41.
10. Boukobza M, Crassard I, Bousser MG, Chabriat H. MR imaging features of isolated cortical vein thrombosis: diagnosis and follow-up. AJNR Am J Neuroradiol. 2009; 30: 344–348.
11. Medel R, Monteith SJ, Crowley RW, Dumont AS. A review of therapeutic strategies for the management of cerebral venous sinus thrombosis. Neurosurg Focus, 2009; 27 (5): E6 (ISSN: 1092-0684).
12. Geisbüsch C, Richter D, Herweh C, Ringleb PA, Nagel S. Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke, 2014 Aug; 45 (8): 2469-71.
13. Anticoli S, Pezzella FR, Scifoni G, Ferrari C, Pozzessere C. Treatment of cerebral venous thrombosis with rivaroxaban. J Biomed Sci. 2016; 5 (3): 1-2.
14. Wasay M, Khan M, Rajput HM, Farooq S, Memon MI, Al-Rukn SA, Malik A, Abd-Allah F, Shoaib RF, Shahid R, Nishat S. New oral anticoagulants versus warfarin for cerebral venous thrombosis: a multi-center, observational study. Journal of Stroke, 2019; 21 (2): 220.
15. Ahmad Y, Lip GY. Stroke prevention in atrial fibrillation: where are we now? Clinical Medicine Insights: Cardiology, 2012; 6: CMC-S8976.
16. Esmaeili S, Abolmaali M, Aarabi S, Motamed MR, Chaibakhsh S, Joghataei MT, Mojtahed M, Mirzaasgari Z. Rivaroxaban for the treatment of cerebral venous thrombosis. BMC Neurology, 2021; 21 (1): 1-6.
17. Maqsood M, Imran Hasan Khan M, Yameen M, Aziz Ahmed K, Hussain N, Hussain S. Use of oral rivaroxaban in cerebral venous thrombosis. Journal of Drug Assessment, 2021; 10 (1): 1-6.
18. Iyer RS, Ramakrishnan TC, Akhtar S, Muthukalathi K, Kumar P, Muthukumar K. Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients. Clinical Neurology and Neurosurgery, 2018; 175: 108-11.
Original Articles